Bioequivalence Study of Olanzapine Tablets, 5 mg Under Fed Study

NCT01503424 | Completed Phase 1 DMC

• 1 other identifier: 379-11
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare the bioequivalence and characterize the profile of the olanzapine tablets, 5 mg with zyprexa tablets, 5 mg in healthy, adult, human subjects under fed conditions and to monitor the adverse events and ensure the safety of the subjects.

Conditions

Fed

Outcome Measures

Primary Outcomes (1)

• Bioequivalence is based on Cmax and AUC parameters

  2 months

Study Arms (2)

Olanzapine Tablets, 5 mg

EXPERIMENTAL

Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited

Drug: Olanzapine

Zyprexa

ACTIVE COMPARATOR

Zyprexa Tablets, 5 mg of Eli Lilly and company

Drug: Olanzapine

Interventions

Olanzapine DRUG

Olanzapine Tablets, 5 mg

Also known as: Zyprexa

Olanzapine Tablets, 5 mg; Zyprexa

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy, adult, human volunteers between 18 and 45 years of age (both inclusive) living in and around Ahmedabad city of western part of IndIa.
• Having a Body Mass Index (BMI) between 18.5 and 24.9(both inclusive), calculated as weight in kg/height in m2.
• Non-smokers since at least six months.
• Have no significant diseases or clinically significant abnormal findings during screening,medical history, clinical examination, laboratory evaluations, 12- lead ECG and X-ray chest (postero-anterior view) recordings.
• Able to understand and comply with the study procedures. in the opinion of the Principal investigator.
• Able to give voluntary written informed consent for participation in the trial.
• In case of female subjects:
• Surgically sterilized at least 6 months prior to study participation or
• If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study.
• Pregnancy test must be negative.

You may not qualify if:

• Known hypersensitivity or idiosyncratic reaction to olanzapine to any of its excipients or any drug or any substance.
• History or presence of any disease or condition which might compromise the haemopoietic,renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
• A recent history of harmful use of alcohol(less than 2 years),ie alcohol consumption of more than 14 standard drinks per week for men and 07 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits such as rum, whisky, brandy etc), or consumption of alcohol or alcoholic product within 48 hrs prior to receiving IMP.
• Inability to remain in an upright position at the time of dosing.
• Sitting blood pressure less than 110/70 mm Hg or pulse rate less than 60 or more than 100 beats per minute at the time of screening.
• Presence of orthostatic hypotension at the time of screening.
• Ingestion or Use of any medication at any time within l4 days prior to dosing in period-1. In any such case subject selection will be at the discretion of the Principal Investigator.
• Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAII)induced urticaria.
• Consumption of Grape fruits or its products within a period of 48 hours prior to receiving the study drug.
• The presence of clinically significant abnormal laboratory values during screening.
• Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
• History or presence of psychiatric disorders.
• A history of difficulty with donating blood.
• Note: In case the blood loss is ≤ 200 mL; subject may be enrolled 60 days after blood donation or last sample of the previous study.
• A positive hepatitis screen including hepatitis B surface antigen and HCV antibodies.

Sponsors & Collaborators

• Dr. Reddy's Laboratories Limited: lead

Study Sites (1)

Lambda Therapeutic Research Ltd.,

Ahmedabad, Gujarat, 380061, India

Location

MeSH Terms

Conditions

Lecithin Cholesterol Acyltransferase Deficiency

Interventions

Olanzapine

Condition Hierarchy (Ancestors)

Hypoalphalipoproteinemias; Hypolipoproteinemias; Lipid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Benzodiazepines; Benzazepines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Alpeshkumar Patel, MD

  Lambda Therapeutic Research Ltd.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 2, 2012
• First Posted: January 4, 2012
• Study Start: August 1, 2011
• Primary Completion: September 1, 2011
• Study Completion: September 1, 2011
• Last Updated: January 5, 2012

Record last verified: 2012-01

Locations

IN (1)